Pressemitteilungen

Nov 04, 2025

Vertrag (PPA) mit 20-jähriger Laufzeit über Lieferung von 16 MW Ökostrom tritt im Dezember 2027 in Kraft

Oct 28, 2025

Merck und Promega werden gemeinsam neue Technologien entwickeln, die die Arzneimittelforschung vorantreiben.

Oct 15, 2025

Zukauf soll Downstream-Processing-Angebot an branchenführenden Filtrations- und Chromatographie-Lösungen ergänzen

Sep 23, 2025

Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry.

Sep 18, 2025

Merck opens first climate-neutral manufacturing facility in Ireland. €150M investment creates 200+ jobs in filter production.

Jul 24, 2025

Merck signed a non-binding MoU with Washington University in St. Louis. The agreement continues their nearly century-long partnership.

Jul 15, 2025

Jun 18, 2025

Merck today announced Neoclease as the winner of the 2025 North American Advance Biotech Grant.

Apr 24, 2025

Merck today launched its global 2025 Curiosity Cube tour.

Jan 23, 2025

Custom robotic workstation automates company’s broad portfolio of biology assays for academia, biotech, and pharma

Jan 06, 2025

HUB internationally recognized pioneer in organoid development

Dec 17, 2024

HUB internationally recognized pioneer in organoid development

Oct 29, 2024

Merck today announced a € 70 million expansion of its ADC manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri, USA.

Oct 09, 2024

Merck has opened its new €290 million biosafety testing facility in Rockville, Maryland, USA.

Sep 10, 2024

MilliporeSigma launched the first single-use reactor specifically designed to manufacture antibody drug conjugates (ADCs).

Sep 03, 2024

Merck today announced that the company’s Life Science business achieved EXCiPACT cGMP certification for PAMs at its major global CCM production sites.

Jul 31, 2024

Merck, a leading science and technology company, today announced the closing of the transaction to acquire Mirus Bio.

Jul 24, 2024

Merck has signed a non-binding MoU with Gene Therapy Research Institution Co., Ltd. (GTRI), a Japanese clinical-stage biotech start-up specializing in gene therapy using adeno-associated virus (AAV) vectors.

Jul 12, 2024

Merck today announced the start of commercial production of its first GMP compliant manufacturing line for cell culture media in China.

Jul 03, 2024

Merck announced that the Life Science business sector entered into a non-binding Memorandum of Understanding (MoU) with Afrigen Biologics to support the development of an mRNA vaccine technology platform.

Jun 18, 2024

SMC^® immunoassay technology from Merck provides new understanding of cell dysfunction to slow disease progression

Jun 11, 2024

Facility to provide production-related quality control services for Life Science business and brings together 135 employees and various functions into one ~10,000 m2 building.

Jun 06, 2024

Expands facility by 25,000 square meters, nearly doubling size, adds new down filling capabilities, distribution space for Life Science customers, employs more than 470 people, including engineers, manufacturing, distribution experts.

Jun 04, 2024

Merck announced today that Siren Biotechnology has been selected as the North American winner of its 13th Advance Biotech Grant Program.

May 29, 2024

Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Technology (KAIST).

May 28, 2024

Merck, a leading science and technology company, has launched its M-Trace^® Software & Mobile App, a comprehensive data tracking solution to digitize sterility testing.

May 22, 2024

Merck, a leading science and technology company, today announced the signing of a definitive agreement to acquire Mirus Bio for US$ 600 million.

Apr 17, 2024

Merck, a leading science and technology company, officially kicked off its global 2024 Curiosity Cube tour today in Darmstadt, Germany.

Apr 16, 2024

Merck, a leading science and technology company, has launched the first all-in-one, validated genetic stability assay of its kind.

Mar 26, 2024

Merck, has expanded its M Lab™ Collaboration Center in Shanghai, the company’s largest in its global network of ten interconnected labs.

Mar 20, 2024

Merck invests more than € 300 million into a new Bioprocessing Production Center in Daejeon, South Korea.

Feb 27, 2024

13,000 square-meters space for Life Science business sector accommodates 11,000 pallet positions and more than 50,000 stock-keeping units.

Jan 24, 2024

Merck announced that the Life Science business sector entered into a non-binding MoU with Mycenax Biotech to explore cooperation to bring innovative and high-capacity bioprocessing solutions to Taiwan and other international markets.

Dec 05, 2023

Combines generative AI, machine learning and computer-aided drug-design to increase the success rate of new drugs and therapies

Nov 21, 2023

Further develops its biosafety testing laboratories to meet local demand; new labs complete 2nd phase of company’s € 29 million Biologics Testing Center opened in 2022.

Nov 14, 2023

Accelerates digitalization in labs and manufacturing by offering traceable digital records of physical reference materials.

Sep 26, 2023

Merck today became the first CTDMO to offer integrated services for all critical stages of mRNA development, manufacturing, and commercialization, including products and testing.

Jul 12, 2023

Lenexa, Kansas, USA facility becomes company’s largest dry powder cell culture media facility and Center of Excellence

Jun 29, 2023

Merck is expanding production capacity for highly purified reagents with a € 70 million investment at Nantong, China manufacturing site.

Jun 06, 2023

Merck announced that Proteologix US Inc. (“Proteologix”) has been selected as the North American winner of its 12th Advance Biotech Grant program.

May 31, 2023

According to a recent study sponsored by Merck, a leading science and technology company, mRNA technology is a “game-changer” for Asia-Pacific (APAC) vaccine manufacturers. Nearly 40 manufacturers participated in the survey.

May 31, 2023

Responds to global demand for biosafety testing for drug development and commercialization. Expansion creates nearly 500 new jobs in Glasgow and Stirling. Company’s investment to boost global testing capacity now tops € 350 million since mid-2022.

May 02, 2023

Merck partners with MOTIE and Daejeon City for a new Asia-Pacific BioProcessing Center to advance life science.

Apr 26, 2023

Over 250 events expected to reach more than 45,000 future scientists on two continents. Hands-on experiments to focus on the impact of contamination on the planet and everyday life.

Apr 24, 2023

Merck, a leading science and technology company, today announced the launch of its Ultimus® Single-Use Process Container Film.

Mar 27, 2023

Partnership to support Beyond Benign’s online learning platform and higher education program

Dec 07, 2022

Non-binding MoU signed between Merck and Synplogen for collaborative initiatives.

Dec 06, 2022

Merck, a leading science and technology company, has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”.

Nov 16, 2022

Merck invests more than € 290 million in its biosafety testing capacity at Rockville, Maryland, USA.

Nov 07, 2022

Merck, a leading science and technology company, today announced a collaboration with Biotheus.

Oct 04, 2022

The Life Science business of Merck has opened a commercial facility for its new Millipore^® CTDMO Services offering at the company’s site in Martillac, France.

Sep 21, 2022

Merck, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the opening of a viral clearance (VC) laboratory as part of the first building phase of its new € 29 million China Biologics Testing Center.

Sep 08, 2022

Merck, a leading science and technology company, strengthens its manufacturing capabilities for single-use assemblies

Aug 08, 2022

Merck, a leading science and technology company, has launched the VirusExpress^® 293 Adeno-Associated Virus (AAV) Production Platform, making it one of the first CDMOs and technology-developers to provide a full viral vector manufacturing offering.

Jul 19, 2022

7,000 solar panels produce energy to power 700 homes, Part of We Energies’ “Solar Now” program, bringing more renewable energy to Wisconsin, Reinforces the company’s long-term commitment to renewable energy.

Jul 18, 2022

New facility to manufacture the company’s Hi-Flow™ Plus lateral flow membrane used in rapid diagnostic test kit manufacturing, including Covid-19.

Jun 21, 2022

Merck doubles high-potent active pharmaceutical ingredients (HPAPI) production capacity at Verona, Wisconsin facility.

Jun 14, 2022

Merck collaborates with Agilent Technologies to advance Process Analytical Technologies (PAT).

May 23, 2022

The investment, which is the largest in a single site ever for the Life Science business sector, significantly increases membrane manufacturing capacities and enables the construction of a new filtration manufacturing facility.

May 18, 2022

Merck today announced that the Life Science business further enhanced its commitment to Science, Technology, Engineering and Math (STEM) education, with the launch of its 2022 Curiosity Cube^® mobile science lab in Europe and North America.

Apr 28, 2022

Merck’s First Asia Pacific Mobius^® Single-Use Manufacturing Center in Wuxi, China

Apr 21, 2022

ReadyStream^® system offers automated media preparation to conveniently provide a large volume of preheated media, eliminates five time-consuming steps.

Apr 14, 2022

ZooMAb^® antibodies first-ever antibody to be recognized for low-environmental impact by My Green Lab

Apr 05, 2022

Merck to become the first company to offer a fully integrated ecosystem for advanced process technologies.

Feb 22, 2022

Merck, the U.S. and Canada Life Science business sector of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD 780 million in cash. The business combination is expected to enable the Life Science business to provide its customers with comprehensive end-to-end contract development and manufacturing organization (CDMO) services across the mRNA value chain. The Life Science business plans to further invest over € 500 million to scale up Exelead’s technology over the next ten years.

Feb 15, 2022

Merck's Life Science business sector has entered into a collaboration with Waters Corporation to build and expand an Extractables and Leachables (E&L) Reference Library to include ion mobility measurements

Feb 07, 2022

Merck today announced several organizational changes and a new operating model to support the long-term growth strategy of the Life Science business sector and to better serve the evolving needs of its global customers.

Jan 26, 2022

Merck, a leading science and technology company, today announced that the Life Science business sector signed a non-binding Memorandum of Understanding (MoU) with ID Pharma, the advanced medical business within I’rom Group, outlining its planned support of the development and manufacturing of leading-edge gene therapy.

Mar 03, 2020

Merck today launched its LANEXO^® Lab Inventory, Safety and Compliance Management System, a new digital laboratory informatics solution designed to drastically reduce time in labs and improve data quality and traceability.

Dec 10, 2018

Merck, a leader in genome editing, today announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based biotechnology company genOway.

Nov 26, 2025